Sugi Predict

Sugi Predict / Compounds / SCHEMBL4086904

SCHEMBL4086904

SCHEMBL4086904

C[C@H](NC(=O)NC(c1ccc(C(=O)Nc2nn[nH]n2)cc1)c1ccc(C2CCCCC2)cc1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 5/20 0.49
▸ EPHX1 P07099 3/20 0.42
▸ LMNA P02545 2/20 0.42
▸ MAPK1 P28482 3/20 0.41
▸ ADCY6 O43306 1/20 0.40
▸ ADCY3 O60266 1/20 0.40
▸ ADCY9 O60503 1/20 0.40
▸ ADCY5 O95622 1/20 0.40
▸ ADCY8 P40145 1/20 0.40
▸ ADCY7 P51828 1/20 0.40
▸ ADCY2 Q08462 1/20 0.40
▸ ADCY1 Q08828 1/20 0.40
▸ ADCY4 Q8NFM4 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ NAMPT P43490 1/20 0.39
▸ PDE2A O00408 2/20 0.39
▸ GIPR P48546 2/20 0.39
▸ PCSK9 Q8NBP7 1/20 0.38
▸ HDAC3 O15379 1/20 0.38
▸ HDAC11 Q96DB2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4088302 1.00 GCGR (0.49) GCGREPHX1LMNAMAPK1ADCY6
SCHEMBL4081953 0.89 GCGR (0.49) GCGREPHX1LMNAADCY6ADCY3
SCHEMBL4086482 0.84 GCGR (0.44) GCGRLMNAADCY6ADCY3ADCY9
SCHEMBL4095409 0.84 GCGR (0.42) GCGRLMNAGIPR
SCHEMBL4082075 0.84 GCGR (0.49) GCGREPHX1LMNAL3MBTL1NAMPT
SCHEMBL4097939 0.83 GCGR (0.49) GCGRLMNAADCY6ADCY3ADCY9
SCHEMBL4087662 0.82 GCGR (0.46) GCGRLMNANAMPTGIPRHDAC3
SCHEMBL4088296 0.81 GCGR (0.59) GCGRGIPR
SCHEMBL4086899 0.81 GCGR (0.59) GCGRGIPR
SCHEMBL4091670 0.81 GCGR (0.43) GCGRLMNAADCY6ADCY3ADCY9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885EPHX1 2751/4885LMNA 3643/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885EPHX1 2751/4885LMNA 3643/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885EPHX1 2751/4885LMNA 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.